45.23

0.95% -0.555

10 X Genomics Inc (TXG)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$45.79

Offen:

$45.81

24-Stunden-Volumen:

101.73K

Relative Volume:

0.03

Marktkapitalisierung:

$5.75B

Einnahmen:

$638.78M

Nettoeinkommen (Verlust:

$-22.66M

KGV:

-259.38

EPS:

-0.1744

Netto-Cashflow:

$122.18M

1W Leistung:

+21.04%

1M Leistung:

+40.76%

6M Leistung:

+113.93%

1J Leistung:

+271.14%

1-Tages-Spanne:

$44.80

$46.02

1-Wochen-Bereich:

$38.33

$46.02

52-Wochen-Spanne:

$11.16

$46.02

10 X Genomics Inc Stock (TXG) Company Profile

Firmenname

10 X Genomics Inc

Sektor

Healthcare (1093)

Branche

Health Information Services (47)

Telefon

(925) 401-7300

Adresse

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Mitarbeiter

1,178

Twitter

@10xgenomics

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

TXG's Discussions on Twitter

Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TXG 10 X Genomics Inc	45.31	5.30B	638.78M	-22.66M	122.18M	-0.1744
VEEV Veeva Systems Inc	196.20	31.97B	3.32B	941.65M	1.64B	5.6161
BTSG Brightspring Health Services Inc	67.54	13.67B	13.65B	169.86M	412.12M	1.0758
TEM Tempus Ai Inc	59.08	10.04B	1.36B	-302.91M	-219.93M	-1.7182
HQY Healthequity Inc	93.85	8.00B	1.34B	230.70M	440.96M	2.6695
HNGE Hinge Health Inc	89.25	6.96B	646.34M	-512.40M	202.76M	-6.6871

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-31	Hochstufung	William Blair	Mkt Perform → Outperform
2025-12-11	Herabstufung	Citigroup	Buy → Neutral
2025-12-02	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-09-11	Eingeleitet	Piper Sandler	Neutral
2025-02-13	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-09-03	Eingeleitet	Leerink Partners	Outperform
2024-07-22	Hochstufung	Jefferies	Hold → Buy
2024-07-18	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-10	Herabstufung	Deutsche Bank	Buy → Hold
2024-06-27	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-25	Herabstufung	Guggenheim	Buy → Neutral
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-05-01	Herabstufung	TD Cowen	Buy → Hold
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Hochstufung	BofA Securities	Underperform → Neutral
2023-07-05	Fortgesetzt	JP Morgan	Overweight
2023-05-10	Eingeleitet	Barclays	Overweight
2023-03-31	Eingeleitet	Stephens	Overweight
2023-02-02	Eingeleitet	UBS	Neutral
2022-12-14	Eingeleitet	Deutsche Bank	Buy
2022-08-18	Herabstufung	Goldman	Neutral → Sell
2022-07-25	Eingeleitet	Canaccord Genuity	Buy
2022-07-15	Herabstufung	BofA Securities	Neutral → Underperform
2022-07-15	Herabstufung	William Blair	Outperform → Mkt Perform
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-09-14	Herabstufung	BofA Securities	Buy → Neutral
2021-03-15	Eingeleitet	William Blair	Outperform
2020-12-02	Eingeleitet	Goldman	Neutral
2020-09-09	Eingeleitet	Morgan Stanley	Overweight
2020-07-10	Eingeleitet	Stifel	Buy
2020-03-05	Eingeleitet	Guggenheim	Buy
2020-01-07	Eingeleitet	Citigroup	Buy
2019-10-07	Eingeleitet	BofA/Merrill	Buy
2019-10-07	Eingeleitet	Cowen	Outperform
2019-10-07	Eingeleitet	JP Morgan	Overweight
2019-09-24	Eingeleitet	Evercore ISI	Outperform

Alle ansehen

10 X Genomics Inc Aktie (TXG) Neueste Nachrichten

Jul 14, 2026

TXG Stock Rallies As Wall Street Hikes Price Targets - StocksToTrade

Jul 14, 2026

10x Genomics Is Maintained at Buy by Canaccord Genuity - Moomoo

Jul 14, 2026

Jul 13, 2026

10x Genomics, Inc. Stock 12‑Month Price Target Raised to $35.46, Implies 17% Downside - TradingView

Jul 13, 2026

Jul 11, 2026

Canaccord Genuity Maintains 10x Genomics (TXG) Buy Recommendation - MSN

Jul 11, 2026

Jul 10, 2026